Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Deciphera Pharmaceuticals, Inc. (DCPH) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results"
08/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer"
05/03/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
05/03/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/03/2023 8-K Quarterly results
04/26/2023 ARS Form ARS - Annual Report to Security Holders:
04/26/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/22/2023 SC 13G Flynn James E reports a 6.1% stake in Deciphera Pharmaceuticals, Inc.
02/14/2023 SC 13G BRAIDWELL LP reports a 6.7% stake in DECIPHERA PHARMACEUTICALS INC
02/14/2023 SC 13G/A ARMISTICE CAPITAL, LLC reports a 7.6% stake in DECIPHERA PHARMACEUTICALS, INC.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A Flynn James E reports a 3.5% stake in Deciphera Pharmaceuticals, Inc.
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 7% stake in Deciphera Pharmaceuticals Inc.
02/08/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/08/2023 SC 13G/A GOLDMAN SACHS GROUP INC reports a 5.7% stake in DECIPHERA PHARMACEUTICALS, INC.
02/07/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/07/2023 10-K Annual Report for the period ended December 31, 2022
02/07/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results"
02/03/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/03/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/20/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement",
"Opinion of Goodwin Procter LLP"
01/20/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
01/18/2023 8-K Quarterly results
01/18/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
01/03/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company",
"Summary of INTRIGUE Efficacy Results of ctDNA Analysis for Patients with Mutations in KIT Exon 11 and 17/18 Only Ripretinib Sunitinib Hazard Ratio/Response Difference Median Progression-Free Survival 14.2 months 1.5 months 0.22 , nominal p value Objective Response Rate 44.4% 0% 44.4% nominal p value = 0.0001 Overall Survival Not Estimable 17.5 months 0.34 , nominal p value = 0.0061 Notes: Data cut as of September 1, 2021; Data cut as of September 1, 2022. Based on the results of the ctDNA analysis and discussions with regulators, the Company plans to initiate the INSIGHT pivotal Phase 3 clinical study of QINLOCK versus sunitinib in second-line GIST patients with mutations in KIT exon 11 and 17/18 only. In the planned study, approximately 54 patients will be randomized 2:1 to either QINLOCK..."
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
09/12/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in- Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology Congress 2022",
"Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology Congress 2022"
08/11/2022 EFFECT Form EFFECT - Notice of Effectiveness:
08/04/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/04/2022 8-K Quarterly results
Docs: "Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy